Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02460224
Title Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS

Facility Status City State Zip Country Details
Columbia University Medical Center SC LAG X2101C New York New York 10032 United States Details
Memorial Sloan Kettering Cancer Center SC New York New York 10065 United States Details
Duke Clinical Research Institute SC Durham North Carolina 27704 United States Details
University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
Cancer Therapy and Research Center UT Health Science Center CTRC 2 San Antonio Texas 78229 United States Details
Huntsman Cancer Institute Huntsman Cancer Institute Salt Lake City Utah 84112 United States Details
Novartis Investigative Site Westmead New South Wales 2145 Australia Details
Novartis Investigative Site Heidelberg Victoria 3084 Australia Details
Novartis Investigative Site Leuven 3000 Belgium Details
Novartis Investigative Site Edmonton Alberta T6G 1Z2 Canada Details
Novartis Investigative Site Toronto Ontario M5G 2M9 Canada Details
Novartis Investigative Site Lyon Cedex 69373 France Details
Novartis Investigative Site Saint-Herblain Cédex 44805 France Details
Novartis Investigative Site Heidelberg 69120 Germany Details
Novartis Investigative Site Wuerzburg 97080 Germany Details
Novartis Investigative Site Hong Kong Hong Kong Details
Novartis Investigative Site Milano MI 20133 Italy Details
Novartis Investigative Site Modena MO 41124 Italy Details
Novartis Investigative Site Fukuoka-city Fukuoka 811-1395 Japan Details
Novartis Investigative Site Singapore 119228 Singapore Details
Novartis Investigative Site Singapore 169610 Singapore Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Madrid 28009 Spain Details
Novartis Investigative Site Taipei 10002 Taiwan Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field